Omrix Biopharmaceuticals Inc.
Sector: Biotechnology - Therapeutics
Medical Field: General Surgery
Technological Field: Biosurgical & passive immunization products
Year Established: 1995
Omrix develops novel technologies to provide safer and more effective options to patients in areas with substantial unmet medical needs, particularly in the areas of biosurgical and passive immunotherapy products. The company utilizes its proprietary protein purification technology, innovative development capabilities, and manufacturing know-how to develop these product lines, often through collaborations with companies whose marketing and sales expertise are a complement to our own areas of specialty.
The biosurgical product line includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. The passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies and infectious diseases and for potential biodefense applications.
OMRIX is headquartered at 630 Fifth Avenue, New York, NY. European regulatory affairs, marketing and logistics support offices are located in Brussels, Belgium, and all biosurgical and passive immunotherapy products are manufactured by OMRIX in Tel Aviv, Israel. OMRIX believes that its current production capacity is sufficient to meet its present output requirements. The Company plans to expand its production capacity by building a new production facility in Jerusalem, Israel. The new facility is expected to be completed in 2009, and the additional production capacity will allow the Company to meet its supply demands for the foreseeable future after 2009.